DARE BIOSCIENCE INC (DARE) Fundamental Analysis & Valuation

NASDAQ:DARE • US23666P2002

Current stock price

2.34 USD
+0.06 (+2.63%)
At close:
2.39 USD
+0.05 (+2.14%)
After Hours:

This DARE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DARE Profitability Analysis

1.1 Basic Checks

  • In the past year DARE has reported negative net income.
  • In the past year DARE has reported a negative cash flow from operations.
  • DARE had negative earnings in each of the past 5 years.
  • DARE had negative operating cash flow in 4 of the past 5 years.
DARE Yearly Net Income VS EBIT VS OCF VS FCFDARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M -30M

1.2 Ratios

  • DARE has a Return On Assets (-41.26%) which is comparable to the rest of the industry.
  • DARE's Return On Equity of -471.37% is on the low side compared to the rest of the industry. DARE is outperformed by 84.82% of its industry peers.
Industry RankSector Rank
ROA -41.26%
ROE -471.37%
ROIC N/A
ROA(3y)-67.11%
ROA(5y)-68.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DARE Yearly ROA, ROE, ROICDARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K -2K -4K -6K -8K

1.3 Margins

  • DARE's Gross Margin of 71.29% is fine compared to the rest of the industry. DARE outperforms 78.01% of its industry peers.
  • The Profit Margin and Operating Margin are not available for DARE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DARE Yearly Profit, Operating, Gross MarginsDARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. DARE Health Analysis

2.1 Basic Checks

  • DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • DARE has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DARE has been reduced compared to 5 years ago.
  • The debt/assets ratio for DARE has been reduced compared to a year ago.
DARE Yearly Shares OutstandingDARE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
DARE Yearly Total Debt VS Total AssetsDARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -8.67, we must say that DARE is in the distress zone and has some risk of bankruptcy.
  • DARE's Altman-Z score of -8.67 is on the low side compared to the rest of the industry. DARE is outperformed by 73.30% of its industry peers.
  • DARE has a Debt/Equity ratio of 1.90. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.90, DARE is doing worse than 81.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF N/A
Altman-Z -8.67
ROIC/WACCN/A
WACC9.46%
DARE Yearly LT Debt VS Equity VS FCFDARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 1.14 indicates that DARE should not have too much problems paying its short term obligations.
  • The Current ratio of DARE (1.14) is worse than 83.77% of its industry peers.
  • DARE has a Quick Ratio of 1.14. This is a normal value and indicates that DARE is financially healthy and should not expect problems in meeting its short term obligations.
  • DARE has a Quick ratio of 1.14. This is in the lower half of the industry: DARE underperforms 77.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.14
DARE Yearly Current Assets VS Current LiabilitesDARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. DARE Growth Analysis

3.1 Past

  • DARE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -140.38%.
  • The Revenue has grown by 10412.24% in the past year. This is a very strong growth!
  • DARE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -53.12% yearly.
EPS 1Y (TTM)-140.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.92%
Revenue 1Y (TTM)10412.24%
Revenue growth 3Y-53.12%
Revenue growth 5YN/A
Sales Q2Q%1700%

3.2 Future

  • DARE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.92% yearly.
  • Based on estimates for the next years, DARE will show a very strong growth in Revenue. The Revenue will grow by 299.87% on average per year.
EPS Next Y47.98%
EPS Next 2Y65.61%
EPS Next 3Y74.81%
EPS Next 5Y54.92%
Revenue Next Year5814.75%
Revenue Next 2Y1047.51%
Revenue Next 3Y607.42%
Revenue Next 5Y299.87%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DARE Yearly Revenue VS EstimatesDARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
DARE Yearly EPS VS EstimatesDARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

1

4. DARE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DARE. In the last year negative earnings were reported.
  • Also next year DARE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DARE Price Earnings VS Forward Price EarningsDARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DARE Per share dataDARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DARE's earnings are expected to grow with 74.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.61%
EPS Next 3Y74.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DARE Dividend Analysis

5.1 Amount

  • DARE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DARE Fundamentals: All Metrics, Ratios and Statistics

DARE BIOSCIENCE INC

NASDAQ:DARE (5/1/2026, 8:19:59 PM)

After market: 2.39 +0.05 (+2.14%)

2.34

+0.06 (+2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength67.7
Industry Growth15.53
Earnings (Last)03-26
Earnings (Next)05-11
Inst Owners8.37%
Inst Owner Change0.78%
Ins Owners0.7%
Ins Owner Change0%
Market Cap34.07M
Revenue(TTM)1.03M
Net Income(TTM)-13.40M
Analysts82
Price Target10.46 (347.01%)
Short Float %1.28%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.25%
Min EPS beat(2)23.04%
Max EPS beat(2)95.47%
EPS beat(4)4
Avg EPS beat(4)39.48%
Min EPS beat(4)15.48%
Max EPS beat(4)95.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)43.64%
Min Revenue beat(2)-79.89%
Max Revenue beat(2)167.18%
Revenue beat(4)1
Avg Revenue beat(4)-28.83%
Min Revenue beat(4)-110.91%
Max Revenue beat(4)167.18%
Revenue beat(8)1
Avg Revenue beat(8)-64.54%
Revenue beat(12)2
Avg Revenue beat(12)-49.39%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.65%
PT rev (3m)-4.65%
EPS NQ rev (1m)17.14%
EPS NQ rev (3m)19.44%
EPS NY rev (1m)-82.14%
EPS NY rev (3m)-82.14%
Revenue NQ rev (1m)-37.52%
Revenue NQ rev (3m)-37.52%
Revenue NY rev (1m)-32.79%
Revenue NY rev (3m)-32.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 33.07
P/FCF N/A
P/OCF N/A
P/B 11.99
P/tB 11.99
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.07
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -41.26%
ROE -471.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.29%
FCFM N/A
ROA(3y)-67.11%
ROA(5y)-68.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 1.9
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.57%
Cap/Sales 37.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1.14
Altman-Z -8.67
F-Score4
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)1005.75%
Cap/Depr(5y)670.12%
Cap/Sales(3y)1968.92%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-140.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.92%
EPS Next Y47.98%
EPS Next 2Y65.61%
EPS Next 3Y74.81%
EPS Next 5Y54.92%
Revenue 1Y (TTM)10412.24%
Revenue growth 3Y-53.12%
Revenue growth 5YN/A
Sales Q2Q%1700%
Revenue Next Year5814.75%
Revenue Next 2Y1047.51%
Revenue Next 3Y607.42%
Revenue Next 5Y299.87%
EBIT growth 1Y42.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-313.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-283.27%
OCF growth 3YN/A
OCF growth 5YN/A

DARE BIOSCIENCE INC / DARE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DARE BIOSCIENCE INC?

ChartMill assigns a fundamental rating of 2 / 10 to DARE.


Can you provide the valuation status for DARE BIOSCIENCE INC?

ChartMill assigns a valuation rating of 1 / 10 to DARE BIOSCIENCE INC (DARE). This can be considered as Overvalued.


What is the profitability of DARE stock?

DARE BIOSCIENCE INC (DARE) has a profitability rating of 1 / 10.


What is the financial health of DARE BIOSCIENCE INC (DARE) stock?

The financial health rating of DARE BIOSCIENCE INC (DARE) is 2 / 10.


Can you provide the expected EPS growth for DARE stock?

The Earnings per Share (EPS) of DARE BIOSCIENCE INC (DARE) is expected to grow by 47.98% in the next year.